

Leukemia & Lymphoma



Cincinnati Children's is a national leader in diagnosing and treating a wide range of leukemias and lymphomas that affect children and young adults. Our expertise includes treating patients with more common diagnoses, such as acute lymphoblastic leukemia (ALL) and Hodgkin lymphoma, and those with rarer diseases, such as post-transplant lymphoproliferative disorder (PTLD) and mixed phenotype acute leukemia (MPAL).

We welcome referrals for children, adolescents and young adults up to age 39.

CONTACT US

For patient referrals:
Phone: **513-517-2234 (CBDI)**
Email: cancer@cchmc.org

For international inquiries:
Phone: **+1-513-636-3100**
Email: international@cchmc.org

www.cincinnatichildrens.org/leukemia

HOW WE'RE DIFFERENT

- We have a large team of physicians dedicated solely to the care of patients with leukemia and lymphoma. They bring years of clinical expertise to treat the most complex and challenging patients, and lead multiple clinical trials for patients with ALL and acute myeloid leukemia (AML).
- We are a national and international referral center for patients with rare and relapsed leukemias and lymphomas. Patients seeking expert care for relapsed blood cancers make up 30% of our program's volume.
- Our treatment team works closely with referring physicians, communicating frequently and coordinating care so patients can return to their communities and medical homes as soon as possible.
- We offer comprehensive genomic characterization of all relapsed and many newly diagnosed cancers. Our goal is to rapidly identify possible therapeutic targets and match patients to the best available clinical trials.
- We have significant experience with CAR T-cell immunotherapy for B-cell leukemias and lymphomas. Cincinnati Children's was an early site for trials of tisagenlecleucel (Kymriah), the first commercially available CAR T product. We offer commercial Kymriah for approved indications. We are also one of a limited number of clinical trial sites in U.S. studying CART in newly diagnosed B-ALL with very high risk features.
- We partner closely with the Cincinnati Children's hematopoietic stem cell transplant (HSCT) program, which is one of the largest pediatric programs of its kind in the U.S. This provides a seamless transition from leukemia/lymphoma therapy to transplant. Specialists at Cincinnati Children's have performed more than 2,300 HSCTs. Our transplant team helped develop stem cell transplant procedures that are the standard of care in more than 200 cancer centers throughout North America.
- Our HSCT team has pioneered novel therapies, including a virus-specific T-cell therapy for patients with viral infections during transplant. We have used this novel therapy for patients with Epstein-Barr virus (EBV-driven) lymphomas in patients with immune deficiencies, including post-transplant lymphoproliferative disorder.



Cincinnati Children's is ranked #3 in cancer.



TREATMENT TEAM

John Perentesis, MD
Director, Division of Oncology
Professor of Pediatrics

Maureen O'Brien, MD, MS
Medical Director, Leukemia & Lymphoma Program

Christine Phillips, MD
Director of Clinical Operations

Erin Breese, MD, PhD

Karen Burns, MD

Ellen Chang, MD, MS

LaQuita Jones, MD

Lynn Lee, MD

Benjamin Mizukawa, MD

Robin Norris, MD, MS

Lauren Pommert, MD

Jeremy Rubinstein, MD, PhD

For urgent issues, or to speak with the specialist on call 24/7, call the Physician Priority Link® at 1-888-987-7997.

For international inquiries, call +1-513-636-3100 or email international@cchmc.org.

FULL SPECTRUM OF CONDITIONS TREATED

We treat patients who have:

- Acute myeloid leukemia (AML)
- Acute lymphoblastic leukemia (ALL)
- Chronic myeloid leukemia (CML), also called chronic myelogenous leukemia
- Hodgkin lymphoma
- Non-Hodgkin lymphoma
- Mixed phenotype acute leukemia (MPAL)
- Myelodysplastic syndromes
- Post-transplant lymphoproliferative disorder
- Leukemia and lymphoma that occur in people who have an increased risk of developing these cancers, including people with Down syndrome, Fanconi anemia and immunodeficiencies

CUTTING-EDGE TREATMENT APPROACHES

We offer access to cutting-edge clinical trials for newly diagnosed patients through both the Children's Oncology Group (COG) national consortium and national consortia for adult oncology trials. For patients with relapsed or refractory disease, we offer a wide portfolio of clinical trials of novel targeted agents and immune therapies as well as close coordination with the HSCT program. We offer all COG Phase 1 trials, as well as early phase trials from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) consortium and industry-sponsored trials. We also offer investigator-initiated trials unique to Cincinnati Children's, such as Vyxeos plus venetoclax (for AML). The Leukemia & Lymphoma program also focuses on comprehensive supportive care to manage side effects and maximize quality of life both during and after therapy.

YOUNG ADULT CANCER CENTER

Young adults (ages 15–39) who are diagnosed with leukemia or lymphoma have unique needs. Their response to therapy and risks for side effects are different compared to older adults and young children. Many face complex personal situations, such as having children of their own, juggling career responsibilities and treatment, coping with multiple comorbidities, experiencing difficulty tolerating medication and more.

The nationally recognized Young Adult Cancer Center at Cincinnati Children's addresses these patients' medical and psychosocial concerns to help them experience the best outcomes and quality of life possible. Our multidisciplinary team of young adult cancer specialists works collaboratively to develop and follow a comprehensive treatment plan.

COMPREHENSIVE FERTILITY CARE AND PRESERVATION PROGRAM

Cincinnati Children's was one of the first hospitals in the United States to focus on fertility preservation in patients receiving intensive therapies for pediatric cancers. Fertility preservation services are available for pubertal patients. In addition, pre-pubertal patients may be eligible for experimental treatment protocols.